After more than three decades at Neurocrine, CEO Kevin Gorman will retire later this year, handing the reins of the $13 billion neuroscience drugmaker over …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
New research led by scientists at La Jolla Institute for Immunology (LJI) suggests that many people already have immune cells on “stand by” to fight
Ivan Cheung, the global leader of Eisai’s Alzheimer’s apparatus, will retire at the end of July, the Japanese drugmaker said Tuesday, just four days after
Erectile dysfunction drugs were associated with reduced risk of Alzheimer’s disease, electronic health record (EHR) data from 270,000 men in the U.K. suggested. Over a